Title: | Evaluation of Echinococcus multilocularis tetraspanins as vaccine candidates against primary alveolar echinococcosis |
Authors: | Dang, Zhisheng Browse this author |
Yagi, Kinpei Browse this author |
Oku, Yuzaburo Browse this author →KAKEN DB |
Kouguchi, Hirokazu Browse this author →KAKEN DB |
Kajino, Kiichi Browse this author →KAKEN DB |
Watanabe, Junichi Browse this author |
Matsumoto, Jun Browse this author |
Nakao, Ryo Browse this author →KAKEN DB |
Wakaguri, Hiroyuki Browse this author |
Toyoda, Atsushi Browse this author |
Sugimoto, Chihiro Browse this author →KAKEN DB |
Keywords: | Echinococcus multilocularis |
Tetraspanin |
Vaccine |
Oncosphere |
Primary alveolar echinococcosis |
Issue Date: | 9-Dec-2009 |
Publisher: | Elsevier Ltd. |
Journal Title: | Vaccine |
Volume: | 27 |
Issue: | 52 |
Start Page: | 7339 |
End Page: | 7345 |
Publisher DOI: | 10.1016/j.vaccine.2009.09.045 |
PMID: | 19782112 |
Abstract: | Echinococcus multilocularis causes an important zoonotic cestode disease. The metacestocle stage proliferates in the liver of intermediate hosts including human and rodents and forms multiple cysts. Recently, members of a transmembrane protein tetraspanin (TSP) family have been used as vaccines against schistosomosis, or as diagnostic antigens for cysticercosis. In this study, seven tetraspanins of E. multilocularis, designated as TSP1 to TSP7, were evaluated for their protective potential against primary alveolar echinococcosis. The large extracellular loop (LEL) region of these tetraspanins was cloned from a full-length enriched cDNA library of E. multilocularis metacestodes and expressed in Escherichia coli as a fusion protein with thioredoxin. Recombinant TSPs were applied as vaccines against an E. multilocularis primary experimental infection in BALB/c mice. Cyst lesions in the livers of vaccinated and non-vaccinated mice were counted. The cyst lesion reduction rates induced by the seven tetraspanins in vaccinated vis-à-vis non-vaccinated mice were: 87.9%, 65.8%, 85.1%, 66.9%, 73.7%, 72.9% and 37.6%. Vaccination conferred protective rates to mice ranging from 0% (TSP5, 6, 7) to maximally 33% (TSP1, 3). The results indicated that recombinant tetraspanins have varying protective effects against primary alveolar echinococcosis and could be used in vaccine development. |
Type: | article (author version) |
URI: | http://hdl.handle.net/2115/42601 |
Appears in Collections: | 人獣共通感染症国際共同研究所 (International Institute for Zoonosis Control) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|